Home » Stocks » ALXO

ALX Oncology Holdings, Inc. (ALXO)

Stock Price: $76.88 USD 8.37 (12.22%)
Updated November 30, 3:51 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 2.85B
Revenue (ttm) 2.40M
Net Income (ttm) n/a
Shares Out 37.11M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $76.88
Previous Close $68.51
Change ($) 8.37
Change (%) 12.22%
Day's Open 68.80
Day's Range 67.59 - 78.00
Day's Volume 106,163
52-Week Range 29.36 - 82.28

More Stats

Market Cap 2.85B
Enterprise Value 2.60B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.11M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.13M
Short Ratio 8.88
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,191.16
PB Ratio 10.09
Revenue 2.40M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 253.72M
Net Cash / Share 6.84
Gross Margin 18.20%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-16.49% downside)
Current: $76.88
Target: 64.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-4.36-1.88
Operating Income-23.98-15.75
Net Income-19.24-13.73
Shares Outstanding20.2518.10
Earnings Per Share-1.15-0.96
Operating Cash Flow-14.25-13.19
Capital Expenditures-0.35-0.65
Free Cash Flow-14.60-13.84
Cash & Equivalents9.028.26
Total Debt5.42-
Net Cash / Debt3.608.26
Book Value-70.64-51.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ALX Oncology Holdings, Inc.
Country United States
Employees 17
CEO Jaume Pons

Stock Information

Ticker Symbol ALXO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALXO
IPO Date July 17, 2020


ALX Oncology Holdings, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.